Please assess the completion status of the following clinical trial:

Trial Title: Desmopressin as a Therapy for Bedwetting in Children With Sickle Cell Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with Hemoglobin SS, SC, SB0thal or SB+thal~2. Patients with at least two episodes of primary nocturnal enuresis per week or four episodes over the two weeks prior to enrollment.~3. Patients with secondary enuresis who have been evaluated and cleared by a pediatric urologist as not having other etiologies of enuresis (e.g. overactive detrusor activity, a genitourinary anatomic abnormality)~Exclusion Criteria:~1. Patients with developmental delay or neurologic dysfunction secondary to stroke.~2. Patients with hypertension or underlying renal disease.~3. Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing normal genitourinary anatomy is sufficient to clear a patient for the study.~4. Patients with daytime urinary incontinence~5. Patients with glucosuria on urinalysis.~6. Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric urologist to rule out other etiologies of enuresis.~7. Patients who are pregnant.~8. Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Desmopressin (Type: None): 0.2mg tablets, dose titrated to effect
- Placebo (Type: None): Placebo Comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).